Brief: Eiger BioPharmaceuticals Inc Announces Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3
20/09/2021 13:26
Sept 20 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ANNOUNCES INTERIM ANALYSIS AND
CONTINUATION OF DOSING OF PEGINTERFERON LAMBDA IN PHASE 3
TOGETHER STUDY OF NEWLY DIAGNOSED COVID-19 OUTPATIENTS
* EIGER BIOPHARMACEUTICALS INC - DATA SAFETY MONITORING
BOARD
RECOMMENDS CONTINUATION OF PEGINTERFERON LAMBDA
Source text for Eikon: ID:nPn54wHrja
Further company coverage: EIGR.O
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview